This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In the January–March 2015 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory K. Bell and other industry experts discuss managing product liability in the pharma and healthcare sector. To read the article, click the link below.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comNavigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Join us for a CRA-moderated panel discussion with leaders in Digital Therapeutics. Learn how key players are reacting to emerging challenges, and which...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...
